Association between statin use on delirium and 30-day mortality in patients with chronic obstructive pulmonary disease in the intensive care unit

Table 5 Odds ratio for delirium and 30-day mortality according to statin use

Group	Delirium					30-day mortality
Group	No. of events/No. (%)	Crude.OR_95CI	p	adj.OR_95CI	p	No. of events/No. (%)	crude.OR_95CI	p	adj.OR_95CI	p
No statin use	237/1241 (19.1)	1 (Ref)		1 (Ref)		269/1241 (21.7)	1 (Ref)		1 (Ref)
Statin use after ICU	68/644 (10.6)	0.5 (0.37–0.67)	< 0.001	0.55 (0.4–0.75)	< 0.001	107/644 (16.6)	0.72 (0.56–0.92)	0.009	0.85 (0.63–1.15)	0.287
Statin use before and after ICU	131/840 (15.5)	0.78 (0.62–0.99)	0.04	0.76 (0.58–1)	0.047	116/840 (13.8)	0.58 (0.46–0.73)	< 0.001	0.55 (0.41–0.73)	< 0.001

Adjusted model in delirium was adjusted for age, SBP, DBP, HR, SpO_2, CAD, asthma, liver disease, ACEI/ARB, antibiotic, glucocorticoids, HGB, PLT, sodium and calcium, norepinephrine, vasopressin, epinephrine, SAPII, OASIS, Los-ICU. Adjusted model in 30-day mortality was adjusted for age, SBP, DBP, HR, RR, SpO_2, CHF, asthma, Diabetes, liver disease, ACEI/ARB, β-blockers, antibiotic, glucocorticoids, WBC, HGB, potassium and sodium, norepinephrine, vasopressin, epinephrine, CCI, SAPII, OASIS, Los-ICU

ISSN: 2047-783X